Biocon Pharma Ltd in partnership with Carnegie Pharmaceuticals LLC receives USFDA tentative approval for Rifaximin Tablets

Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, in partnership with Carnegie Pharmaceuticals LLC, received tentative approval from the U.S. Food and Drug Administration (U.S. FDA) for the ANDA for Rifaximin Tablets, 550 mg.

Rifaximin tablets are a rifamycin antibacterial indicated for reducing the risk of overt hepatic encephalopathy (HE) recurrence and to treat irritable bowel syndrome with diarrhea (IBS-D) in adults.

Shares of Biocon Limited was last trading in BSE at Rs. 347.25 as compared to the previous close of Rs. 352.10. The total number of shares traded during the day was 348425 in over 1465 trades.

The stock hit an intraday high of Rs. 352.75 and intraday low of 344.60. The net turnover during the day was Rs. 121077906.00.

Source : Equity Bulls

Keywords

Biocon INE376G01013 Biotechnology BioconPharma Partnership CarnegiePharmaceuticalsLLC USFDA TentativeApproval RifaximinTablets